| Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy F Rossari, F Minutolo, E Orciuolo Journal of hematology & oncology 11, 1-14, 2018 | 333 | 2018 |
| Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-TNF: neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio L Bertani, F Rossari, B Barberio, MG Demarzo, G Tapete, E Albano, ... Inflammatory bowel diseases 26 (10), 1579-1587, 2020 | 51 | 2020 |
| Tumor dormancy as an alternative step in the development of chemoresistance and metastasis-clinical implications F Rossari, C Zucchinetti, G Buda, E Orciuolo Cellular Oncology 43, 155-176, 2020 | 42 | 2020 |
| Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models F Birocchi, M Cusimano, F Rossari, S Beretta, PMV Rancoita, A Ranghetti, ... Science translational medicine 14 (653), eabl4106, 2022 | 40 | 2022 |
| Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients M Persano, M Rimini, T Tada, G Suda, S Shimose, M Kudo, J Cheon, ... European Journal of Cancer 189, 112933, 2023 | 21 | 2023 |
| Gene-based delivery of immune-activating cytokines for cancer treatment F Rossari, F Birocchi, L Naldini, N Coltella Trends in Molecular Medicine 29 (4), 329-342, 2023 | 9 | 2023 |
| Tissue-and liquid biopsy-based biomarkers for immunotherapy in breast cancer L Licata, M Mariani, F Rossari, G Viale, G Notini, MM Naldini, C Bosi, ... The Breast 69, 330-341, 2023 | 7 | 2023 |
| α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma F Rossari, T Tada, G Suda, S Shimose, M Kudo, C Yoo, J Cheon, ... International Journal of Cancer 154 (6), 1043-1056, 2024 | 5 | 2024 |
| The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia D Magliulo, M Simoni, C Caserta, C Fracassi, S Belluschi, K Giannetti, ... EMBO Molecular Medicine 15 (11), e17810, 2023 | 2 | 2023 |
| 185P Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study F Rossari, T Tada, S Shimose, M Kudo, C Yoo, J Cheon, F Finkelmeier, ... Annals of Oncology 34, S1547, 2023 | 2 | 2023 |
| Past, present, and future of FGFR inhibitors in cholangiocarcinoma: From biological mechanisms to clinical applications E Amadeo, F Rossari, F Vitiello, V Burgio, M Persano, S Cascinu, ... Expert Review of Clinical Pharmacology 16 (7), 631-642, 2023 | 2 | 2023 |
| Role of Circulating DNA in the Precocious Diagnosis of Lymphoma: an example in a Transplant-Related Aggressive Lymphoma L Biavati, F Rossari, E Orciuolo, MI Ferreri, C Zucchinetti, U Boggi, ... Clinical Oncology and Research 2 (2), 2-5, 2019 | 2 | 2019 |
| Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab M Rimini, B Stefanini, T Tada, G Suda, S Shimose, M Kudo, F Finkelmeier, ... Liver International 44 (5), 1108-1125, 2024 | 1 | 2024 |
| Different genomic clusters impact on responses in advanced biliary tract cancer treated with cisplatin plus gemcitabine plus durvalumab M Rimini, E Loi, MD Rizzato, T Pressiani, C Vivaldi, E Gusmaroli, ... Targeted Oncology 19 (2), 223-235, 2024 | 1 | 2024 |
| Interferon-alpha gene delivery by tumor-associated macrophages improves function and prevents exhaustion of B7-H3-redirected CAR T cells in glioblastoma F Rossari, F Birocchi, M Cusimano, A Ranghetti, G Orofino, LS Sergi, ... HUMAN GENE THERAPY 32 (19-20), A33-A33, 2021 | 1 | 2021 |
| Persistence of periodic breathing/cheyne-stokes respiration after tilt table test during short term respiratory monitoring in patients with systolic heart failure C Borrelli, F Gentile, F Rossari, P Sciarrone, C Passino, G Mirizzi, ... Journal of the American College of Cardiology 71 (11S), A923-A923, 2018 | 1 | 2018 |
| Mechanics and Chemistry of Respiration in Health: A Synopsis of the Regulation of Breathing C Passino, E Cacace, D Caratozzolo, F Rossari, LF Saccaro The Breathless Heart: Apneas in Heart Failure, 11-33, 2017 | 1 | 2017 |
| Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: a large real-life worldwide population M Rimini, L Fornaro, MD Rizzato, L Antonuzzo, F Rossari, T Satake, ... European Journal of Cancer, 114199, 2024 | | 2024 |
| Treatment options for advanced hepatocellular carcinoma: the potential of biologics F Rossari, S Foti, S Camera, M Persano, A Casadei-Gardini, M Rimini Expert Opinion on Biological Therapy, 1-16, 2024 | | 2024 |
| 184P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB) M Persano, M Rimini, S Foti, S Camera, F Rossari, E Amadeo, F Vitiello, ... Annals of Oncology 35, S83, 2024 | | 2024 |
